Join the Bladder Cancer group to help and get support from people like you.
Bladder Cancer News
Related terms: Cancer, Bladder
Firefighters at Higher Risk for Many Cancers
WEDNESDAY, July 30, 2025 — Firefighters work hard saving lives, and in process put their own lives at heightened risk from skin, kidney and other types of cancers, a new American Cancer Society (ACS) ...
Deion Sanders Shares Bladder Cancer Journey, Urges Others to Get Checked
WEDNESDAY, July 30, 2025 — University of Colorado football coach Deion Sanders says he is now cancer-free after an unexpected battle with bladder cancer. Now he’s encouraging others to take charge of ...
Autoantibodies Influence Cancer Response To Immunotherapy, Study Says
MONDAY, July 28, 2025 — Cutting-edge immunotherapy drugs are incredibly effective against some cancers but barely put a dent in others – and researchers might now know why. Patients’ own autoa...
FDA Approves Zusduri (mitomycin) for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--Jun. 12, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and s...
FDA Approves Imfinzi (durvalumab) for Muscle Invasive Bladder Cancer
On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant...
Multiparametric MRI Expedites Treatment in Muscle-Invasive Bladder Cancer
FRIDAY, Jan. 24, 2025 – Incorporating multiparametric magnetic resonance imaging (mpMRI) for initial staging can reduce the time to correct treatment (TTCT) for patients with muscle-invasive bladder...
New Therapy Helps Patients With Tough-to-Treat Bladder Cancers
FRIDAY, Dec. 6, 2024 – There's new hope for people battling advanced bladder cancer who do not respond to first-line therapy, researchers report. An experimental new drug with the unwieldy name of...
MS Might Raise a Person's Odds for Cancer
THURSDAY, Oct. 10, 2024b – There's a small but significant increased of certain cancers in people battling multiple sclerosis (MS), new research shows. Those malignancies include cancers of the...
Extended Lymphadenectomy Fails to Improve Survival in Bladder Cancer
THURSDAY, Oct. 3, 2024 – For patients with muscle-invasive bladder cancer, extended lymphadenectomy does not improve disease-free or overall survival compared with standard lymphadenectomy,...
Post-Op Keytruda Boosts Bladder Cancer Outcomes
WEDNESDAY, Sept. 18, 2024 – When given after organ-removal surgery, Keytruda brings patients battling advanced bladder cancers more time cancer-free, a new trial finds. Folks with "high-risk"...
Socioeconomic Disparities Impact Immunotherapy Use in Urologic Cancers
FRIDAY, Sept. 6, 2024 – Immunotherapy (IO) utilization is increasing over time, but significant socioeconomic disparities exist for patients with advanced clear cell renal cell carcinoma (ccRCC) and...
Ruling Out Other Conditions Needed With Suspected Interstitial Cystitis
WEDNESDAY, Sept. 4, 2024 – Efforts to rule out bladder tumors and tuberculosis are still essential in the follow-up of patients with suspected interstitial cystitis (IC), according to a study...
FDA Approves Anktiva (nogapendekin alfa inbakicept-pmln) Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CULVER CITY, Calif., April 22, 2024 -- ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved Anktiva (N-803, or ...
Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Padcev plus pembrolizumab approved based on groundbreaking EV-302 trial Confirmatory trial found Padcev plus pembrolizumab nearly doubled median overall survival compared to standard of care...
FDA Approves Adstiladrin (nadofaragene firadenovec-vncg) for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Ferring’s novel adenovirus vector-based gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) is the first gene therapy approved for bladder cancer Efficacy and safety of Adstiladrin supported by...